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ABSTRACT
Trastuzumab (TZM), a monoclonal antibody against the ERBB2 protein, increases survival in ERBB2-
positive breast cancer patients. Its clinical use, however, is limited by cardiotoxicity. We sought to
evaluate whether TZM cardiotoxicity involves inhibition of human adult cardiac-derived stem cells,
in addition to previously reported direct adverse effects on cardiomyocytes. To test this idea, we
exposed human cardiosphere-derived cells (hCDCs), a natural mixture of cardiac stem cells and
supporting cells that has been shown to exert potent regenerative effects, to TZM and tested the
effects in vitro and in vivo.We found that ERBB2mRNA and protein are expressed in hCDCs at levels
comparable to those in humanmyocardium. Although clinically relevant concentrations of TZM had
no effect on proliferation, apoptosis, or size of the c-kit-positive hCDC subpopulation, in vitro assays
demonstrated diminished potential for cardiogenic differentiation and impaired ability to form
microvascular networks in TZM-treated cells. The functional benefit of hCDCs injected into the
border zone of acutely infarcted mouse hearts was abrogated by TZM: infarcted animals treated
with TZM hCDCs had a lower ejection fraction, thinner infarct scar, and reduced capillary density
in the infarct border zone compared with animals that received hCDCs alone (n  12 per group).
Collectively, these results indicate that TZM inhibits the cardiomyogenic andangiogenic capacities of
hCDCs in vitro and abrogates the morphological and functional benefits of hCDC transplantation in
vivo. Thus, TZM impairs the function of human resident cardiac stem cells, potentially contributing
to TZM cardiotoxicity. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:289–297
INTRODUCTION
Breast cancer is the most prevalent form of can-
cer in women. In 2012, an estimated 226,870
women will be diagnosed with breast cancer in
the U.S., and more than 39,510 will die from this
disease [1]. Tyrosine kinase inhibitors have be-
come an important treatment option for breast
cancer patients. A series of large-scale studies
have shown that trastuzumab (TZM) (Herceptin;
Genentech, Inc., South San Francisco, CA, http://
www.gene.com) a monoclonal antibody target-
ing the HER2/neu (ERBB2) tyrosine kinase, can
substantially reduce the risk of recurrence and
early death in women with ERBB2-positive
breast cancer [2–4]. However, the use of TZM
has been associated with adverse cardiovascular
effects. The incidence of cardiac dysfunction
ranged from 4% to 7% with TZM monotherapy
but reached up to 27% when the regimen also
included anthracyclines [4, 5]. Additionally, pre-
existing cardiac dysfunction, common in the
older breast cancer population, calls for frequent
monitoring to detect further functional deterio-
ration, which usually requires temporary or per-
manent cessation of this important therapy. In
this study, we sought to better understand the
pathophysiologic basis of TZM-associated car-
diotoxicity and hypothesized that cardiac dys-
function induced by TZM may be mediated, at
least in part, by adverse effects on endogenous
cardiac stem cells. The cardiac progenitor cell
population used in the present study was iso-
lated fromexplant cultures of adult humanendo-
myocardial biopsies using an intermediate car-
diosphere (CSp) step. CSps are self-assembling
spherical clusters that constitute a niche-like en-
vironment with undifferentiated cells proliferat-
ing in the core and cardiac-committed cells on
the periphery [6–8]. Human cardiosphere-de-
rived cells (hCDCs) can be expandedmany fold as
monolayers, achieving cell numbers suitable for
cell therapy (as in the ongoing CADUCEUS trial;
NCT00893360, http://clinicaltrials.gov). Our pre-
viouswork onhCDCs [7–9] and that of others [10,
11] support the notion that such cells can directly
regenerate myocardium and blood vessels. The
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fact that cardiosphere-derived cells (CDCs) are also clonogenic
qualifies them as cardiac-derived stem cells [12]. In the present
study, we investigated whether functional impairment of hCDCs
could contribute to TZM-induced cardiotoxicity in vitro and in
vivo.
MATERIALS AND METHODS
Biopsy Specimen Processing and Cell Culture
Percutaneous endomyocardial biopsy specimens (n 12) were
obtained from the right ventricular septal wall during clinically
indicated procedures after informed consentwas obtained, in an
institutional review board-approved protocol. CDCs were iso-
lated from these humanmyocardial specimens as described pre-
viously [7–9]. Human dermal fibroblasts and the breast cancer
cell line MCF-7 served as controls and were cultured in the same
medium as hCDCs.
Reverse Transcription SYBR Green Polymerase Chain
Reaction (Quantitative Reverse Transcription-
Polymerase Chain Reaction)
Total RNA was extracted from hCDCs using the RNeasy RNA ex-
traction kit (Qiagen, Valencia, CA, http://www.qiagen.com). RNA
samples were treated with RNase-free DNase Set (Qiagen) to
eliminate genomic DNA contamination, and complementary
DNA was synthesized from 1 g of total RNA using AffinityScript
multiple temperature reverse transcriptase (Stratagene, La Jolla,
CA, http://www.stratagene.com) and oligo(dT)12–18 primer (In-
vitrogen, Carlsbad, CA, http://www.invitrogen.com) following
the manufacturer’s instructions.
Primers for the genes of interest were designed using the
National Center for Biotechnology Information primer design
tool Primer-BLAST. Specificity of the primers was confirmed by
a single band of the polymerase chain reaction (PCR) product
on an agarose gel and a single peak of the dissociation curve
(SYBR Green reverse transcription [RT]-PCR). Gene expression
was normalized to ribosomal protein 18S. RT-PCR was per-
formed in duplicate for each sample with 25 ng of cDNA and
300 nmol/l primer in the Applied Biosystems 7900HT RT-PCR
system (Applied Biosystems, Foster City, CA, http://www.
appliedbiosystems.com) using the QuantiTect SYBR Green PCR
Kit according to the recommendations of themanufacturer (Qia-
gen) as previously described [13]. Human control RNA was pur-
chased from BioChain (BioChain Institute, Inc., Hayward, CA,
http://www.biochain.com).
Myocardial Infarction, Cell Injection,
and Echocardiography
Myocardial infarction was created in adult male SCID-beigemice
10–20 weeks of age as described previously [8] under an ap-
proved animal protocol. CDCs were injected in a total volume of
10 l of phosphate-buffered saline (PBS) at two sites bordering
the infarct, as previously described [8]. PBS and human skin fi-
broblasts served as negative controls. All mice underwent echo-
cardiography before and immediately after surgery (baseline)
and 3 weeks after surgery. Left ventricular ejection fraction and
fractional areawere calculatedwith VisualSonics v1.3.8 software
(VisualSonics Inc., Toronto, http://www.visualsonics.com) from
two-dimensional long-axis views taken through the infarcted
area [8]. To account for the shorter half-life of TZM in mice com-
paredwith patients, animals in the TZM group received biweekly
intraperitoneal injections of 20 mg TZM/kg for 3 weeks [14].
Flow Cytometry
Flow cytometry was used to quantify the percentage of ERBB2
and c-kit-positive hCDCs after staining with a human ERBB2 an-
tibody, followed by staining with an anti-rabbit Alexa 647 sec-
ondary antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
http://www.scbt.com). Likewise, the percentage of dead and ap-
optotic hCDCs was determined by flow cytometry using 7-ami-
noactinomycin andAnnexin V-APC (BDBiosciences, San Jose, CA,
http://www.bdbiosciences.com), respectively.
Functional In Vitro Assays for Proliferation,
Angiogenesis, and Cardiac Differentiation
Proliferation of control and TZM-treated hCDCs was assessed
using the colorimetric WST-8 assay (Cell Counting Kit-8; Dojindo
Molecular Technologies, Gaithersburg, MD, http://www.
dojindo.com). Cells were incubated with 10l of WST-8 tetrazo-
lium salt for 2 hours, and absorbance was measured at 450 nm
(Spectramax M2; Molecular Devices, Sunnyvale, CA, http://
www.moleculardevices.com). Proliferation experiments were
repeated five times, with each condition tested in triplicate.
In vitro angiogenesis assays were performed as recom-
mended by the manufacturer (Becton, Dickinson and Company,
Franklin Lakes, NJ, http://www.bd.com) in triplicate in a 96-well
plate with 104 hCDCs in endothelial growth medium (Cambrex,
Walkersville, MD, http://www.cambrex.com). Vascular tube for-
mation was documented within 5 hours after plating of hCDCs
using an inverted microscope. Human umbilical vascular endo-
thelial cells (HUVECs) served as positive control. A2magnifica-
tion lens covering the entire well and a Nikon digital camera
(Nikon, Tokyo, http://www.nikon.com) were used to document
vascular tube formation. Quantification was performed using
NIH ImageJ software.
A third-generation lentiviral vector systemwas used to trans-
duce hCDCs with the firefly luciferase reporter gene under the
transcriptional control of the cardiac-specific promoter of the
sodium-calciumexchanger, as described previously [13]. In brief,
low passage number hCDCs (6 passages) were plated at 2 
104 cells perwell in a 24-well plate and transducedwith lentivirus
(4.5 104 pg of p24, corresponding to amultiplicity of infection,
i.e., the ratio of infectious agents [virus] to infection targets
[cells], of 35) in a total volume of 2ml in the presence of 8g/ml
polybrene. Sixteen hours later, viral vector-containing medium
was replaced with fresh medium, and cells were incubated with
medium containing 1 g/ml of the small molecules compounds
JL-265-037 and JL-265-010 (kindly provided by Dr. Jay Schneider,
University of Texas Southwestern Medical Center, Dallas, TX),
shown to bepotent inducers of cardiac differentiation [13, 15], in
the presence and absence of TZM. Luciferase activity was mea-
sured 12 days after transduction, using an in vitro luciferase as-
say (Promega, Madison, WI, http://www.promega.com) as per
the manufacturer’s protocol with a Monolight 2010 luminom-
eter (Analytical Luminescence Laboratory, San Diego). Twenty
microliters of each sample (cell lysate) was mixed with 100 l of
luciferase assay reagent (Promega) in 75-mm glass tubes (VWR
International, LLC, Radnor, PA, http://www.vwr.com) and placed
in the instrument (2-second measurements). Results were re-
ported as relative light units normalized to cell number.
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Measurement of Infarct Size, Scar Thickness,
and Capillary Density
In a subset of infarcted animals (hCDCs PBS, n 5; hCDCs
TZM, n  5), hearts were excised under deep anesthesia,
trimmed of the atria, washedwith saline, embedded in O.C.T. com-
pound (SakuraFinetek,Torrance,CA,http://www.sakura.com),and
frozen in a bath of 2-methylbutane with dry ice. The hearts were
stored at80°C until they were sliced transversely with a cryostat
at 6 m thickness with 500 m between sections. Sections were
mounted on glass slides and stained with Masson trichrome [16].
Infarct thickness was measured in three or four consecutive
sections.
For capillary staining, sections were incubated with fluorescein
isothiocyanate-conjugated isolectin B4 antibody (Vector Laborato-
ries, Burlingame, CA, http://www.vectorlabs.com), which has been
reported to beuseful as amarker for endothelial cells fromhumans
and nonprimates. Coincubation of isolectin B4 with 500mM galac-
tosewas used as a negative control. The ImageJ softwarewas used
for binary threshold of fluorescent images for each channel and
consequent particle count. Green pixels were normalized to the
number of mouse nuclei (stained with 4,6-diamidino-2-phenylin-
dole) in the infarct border zone area [9].
Statistical Analysis
All results are presented as mean SEM. Significance of differ-
ences between any two groups was determined by Student’s t
test. A final value of p  .05 was considered significant for all
analyses. All probability values reported are two-sided.
RESULTS
ERBB2 mRNA and Protein Are Expressed in
Human CDCs
Among the different ERBB isoforms, ERBB2 mRNA was found to
be most abundant in hCDCs, followed by ERBB1 and ERBB3,
whereas ERBB4 mRNA was not detected. At the transcript level,
comparable levels of ERBB2 were identified in hCDCs and in hu-
man right ventricular and right atrial myocardium from nonfail-
ing control hearts (Fig. 1A). In addition, a significant proportion of
hCDCs also expressed ERBB2 protein, as assessed by flow cytom-
etry (20 3%, n 4; Fig. 1B).
In Vitro Effects of Trastuzumab on Human CDCs
At clinically relevant concentrations (100 g/ml), TZM did not
slow proliferation of hCDCs, nor did it increase the percentage of
apoptotic cells or alter the c-kit-positive cell population (Fig. 1C,
1D). Of note, no effect on proliferationwas seenwhen cells were
incubatedwith TZM for up to 21 days. To study longer exposures
with TZM, cells were first incubated for up to 13 days with 100
g/ml TZM, and then proliferation was measured with the
WST-8 assay (Fig. 1C). Nevertheless, assessment of cell number
and viability may not entirely reflect the functional capacity of
cells in vivo [17]; thus, additional testing is required to verify
proper cell function. As hCDCs express vascular markers, includ-
ing CD31 and CD34, at the mRNA and protein levels (Fig. 2A and
2B, respectively), we tested the cells’ ability to form vascular
tubes in an in vitro angiogenesis assay. As compared with HU-
VECs, which are the gold standard for this angiogenesis assay,
Figure 1. ERBB2 mRNA and protein expression in human CDCs. (A): Reverse transcription-polymerase chain reaction shows expression of
ERBB isoforms in human myocardium (RV and RA both obtained from a nonfailing human control heart) and hCDCs isolated from three
different patients. 18S RNA served as a control. (B): Representative analysis of ERBB2 protein quantified by flow cytometry (20 3%of hCDCs
expressed ERBB2 protein, n  4). The breast cancer cell line MCF-7, known to express ERBB2, served as positive control. (C): In vitro
proliferation of human cardiosphere-derived cells (hCDCs) was not affected by TZM. No statistically significant differences were seen for
proliferation of freshly isolated hCDCs (days 1–8) versus hCDCs that were first incubated for up to 13 dayswith TZM, and proliferation on days
14–21 was then measured using the WST-8 assay (at least n  4 different hCDCs isolates for each condition). (D): TZM did not change the
percentage of apoptotic or c-kit-positive hCDCs (n 5 different human CDCs). Abbreviations: hCDC, human cardiosphere-derived cell; NS, not
significant; RA, right atrium; RV, right ventricle; TZM, trastuzumab.
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vascular tubes formed more quickly with hCDCs (4 hours for
hCDCs vs. 9–16 hours for HUVECs; Fig. 2C). However, there was
no difference in the complexity of vascular networks formed by
HUVECs andhCDCs (assessedby the number of branching points;
data not shown). At later time points (8–12 hours), hCDCs then
involuted to form a central cell cluster from which secondary
vascular structures started to migrate out within the following
days. The initially linear sprouts of endothelial cells progressively
branched, anastomosed, and formed a microvascular network
that covered the entire well after 12–20 days (Fig. 2D). Thus, this
late migratory response seen on Matrigel resembles the out-
growth seen with the aortic ring assay. Importantly, the size and
complexity of the microvascular network were significantly
greater in the control compared with the TZM group: continued
incubation with TZM-containingmedium slowed the growth and
reduced the complexity of the microvascular network by50%
(Fig. 3A, 3B).
In addition to the adverse effects on angiogenesis, TZM led to
an impairment of cardiac differentiation of hCDCs in vitro, which
became apparent when the cells were incubated with cardio-
genic sulfonyl hydrazone compounds [13, 15]. Using a previously
validated system for testing cardiac differentiation in vitro (car-
diac-specific promoter of the sodium-calcium exchanger [NCX1]
driving the expression of firefly luciferase [13]), we found lu-
ciferase activity under control conditions to be significantly
higher than after incubation with 100 g/ml TZM, when hCDCs
were exposed to two known cardiogenic sulfonyl hydrazone
compounds (JL-265-010 and -037; Fig. 4A). In agreement with
these results, the expression of transcripts indicative of early
cardiac differentiation, including pro-brain natriuretic peptide,
cardiac troponin I, and SERCA2, was more than twofold higher
in the control versus the TZM group (Fig. 4B). Previously, we
demonstrated that NCX1-green fluorescent protein-positive
CDC subpopulations showed prolonged expression of a vari-
ety of additional cardiac markers, including L-type calcium
channel and the cardiac-specific transcription factors GATA4
and TBX5 [13].
In Vivo Effects of Trastuzumab on hCDCs in the
Infarcted Heart
In various studies, we [8, 9, 18–20] and others [10, 21, 22] have
demonstrated a consistent benefit of transplanted CDCs on ven-
tricular function in small and large animal models of acute myo-
cardial infarction. Given that TZM inhibits the cardiomyogenic
and angiogenic capacities of hCDCs in vitro, we tested the hy-
pothesis that TZM abrogates the functional benefits of hCDC
transplantation in vivo. Biweekly injections of TZM over a period
of 3 weeks did not lead to left ventricular dysfunction in healthy
mice (Fig. 5A). In contrast, when hCDCs were injected into the
border zone of acutely infarcted murine left ventricular myocar-
dium, biweekly intraperitoneal administration of TZMabrogated
the functional benefit of hCDCs, as evidenced by a lower ejection
fraction in animals that received hCDCs and TZM compared with
hCDCs alone. Of note, there was no difference in the baseline
ejection fraction after acute myocardial infarction between the
study groups (data not shown). Although hCDCs alone (hCDC
PBS) improved function, consistent with previous reports [8, 9,
20, 23], the hCDCs  TZM group and the two control groups
Figure 2. In vitro angiogenesis assay. Endothelial markers CD31 and CD34 were expressed at the mRNA level (A) and protein level (B).
In summary, 15  7% and 7  2% of hCDCs expressed CD31 and CD34 protein, respectively; n  6. (C): Tube formation on Matrigel
angiogenesis assay was similar in hCDCs (top) and HUVECs (bottom). Magnification,10. (D): Representative images of a time-course
experiment. Early angiogenic response after 4 hours was highlighted by formation of vascular tubes giving rise to a complex mesh-like
structure. After 24 hours, cells formed a central cluster in the middle of the well (top right). Several days later, cells started migrating
out from the central cell cluster, gradually covering the entire well over the next 2–3 weeks (bottom). Magnification,4 (top) and10
(bottom). Abbreviations: d, days; h, hours; hCDCs, human cardiosphere-derived cells; HUVEC, human umbilical vein endothelial cells;
RA, right atrium; RV, right ventricle.
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(injection of human dermal fibroblasts or injection of PBS) were
indistinguishable in terms of ejection fraction (Fig. 5B). Addition-
ally, animals injectedwith hCDCsPBS exhibited less thinning of
infarctedwalls and a tendency to lower infarct area than animals
in the TZM group, signifying that TZM prevents the beneficial
effects of hCDCs on postischemic remodeling (Fig. 5C). Left-ven-
tricular end-systolic and end-diastolic dimensions were not sta-
tistically different between groups at 3 weeks.
The profound antiangiogenic effects observed in vitro
prompted us to test the hypothesis that TZM adversely affects
the density of capillaries in vivo. As a result, we found that the
capillary density (detected by isolectin B4 staining and nor-
malized to the number of nuclei) was significantly reduced in
the infarct border zone of animals that received hCDCs and
TZM compared with animals that received hCDCs alone (Fig.
6A, 6B).
DISCUSSION
Trastuzumab, a recombinant humanized monoclonal anti-
body against the tyrosine kinase receptor ERBB2, dramatically
improves survival in patients with advanced breast cancer.
However, initial studies in metastatic disease revealed a sur-
prisingly high incidence of congestive heart failure, especially
Figure 3. Effect of TZM on in vitro angiogenesis. (A): The size and complexity of the microvascular network on Matrigel matrix after 17
days in culture differed significantly between control and TZM-treated hCDCs. (B): Continued incubation with TZM-containing medium
slowed the growth and reduced the complexity of the microvascular network by 50% (n 8 different human CDCs, each plated and
analyzed in triplicate for control and TZM groups). Abbreviations: a.u., arbitrary units; hCDC, human cardiosphere-derived cells; TZM,
trastuzumab.
Figure 4. In vitro assay for early cardiogenic differentiation. CDCs were transduced with lentiviral vectors expressing firefly luciferase
under the transcriptional control of the cardiac-specific promoter of the sodium-calcium exchanger. Subsequently, hCDCs were incu-
bated for 11 days with control medium, medium  DMSO, or medium with either of the two cardiogenic sulfonyl hydrazone com-
pounds, JL-265-010 and JL-265-037. Then, luciferase activity was determined with in vitro luciferase assays, and results were normal-
ized to cell number. (A): Cardiogenic differentiation was significantly inhibited by TZM compared with control (n 5). (B): Quantitative
real-time reverse transcription-polymerase chain reaction showed expression of cardiac-specific mRNAs, including NPPB, TPMA,
TNNI3, and ATP2A2, to be twofold higher in the control versus the TZM group (n  5, p  .05 for all comparisons). Abbreviations:
ATP2A2, SERCA2; DMSO, dimethyl sulfoxide; NPPB, pro-brain natriuretic peptide; RLU, relative light units; TNNI3, cardiac troponin I;
TPMA, tropomyosin; TZM, trastuzumab.
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in patients who were concurrently treated with anthracy-
clines. More recent adjuvant studies in early-stage breast can-
cer incorporating well-designed prospective cardiac monitor-
ing suggest a lower incidence of symptomatic heart failure (up
to 4% when anthracycline and TZM are given in a sequential
fashion) [24, 25]. TZM cardiotoxicity appears to be dose-inde-
pendent and largely reversible, suggesting a mechanism dif-
ferent from that of anthracyclines [26, 27]. In recent years,
several studies have shed light on the role on ERBB receptors
and its main ligand neuregulin 1 (NRG-1) in the developing
and mature heart. Neuregulin-ERBB signaling is essential for
cardiac development [28–30] and for growth and survival in
cultured neonatal and adult rat myocytes [31]. Importantly,
postnatal disruption of NRG-1/ERBB signaling by gene target-
ing in mice leads to dilated cardiomyopathy [32], mimicking
TZM-associated cardiotoxicity.
Here, we have tested the hypothesis that TZM-associated
cardiotoxicity may be mediated by direct adverse effects of TZM
on adult cardiac stem cells, in addition to adverse effects on
cardiomyocytes. Even though the mammalian heart has been
traditionally viewed as a terminally differentiated postmitotic
organ, the concept of endogenous cardiac regeneration is now
firmly established; through use of radiocarbon dating of human
post-mortem cardiac tissue, it has been documented that cardi-
omyocyte turnover in the adult human heart occurs at an age-
dependent rate of 0.4%–1% per year, with	40% of the mature
heart composed of postnatally generated myocytes [33]
(whereas a recent study using immunohistochemistry reported
strikingly higher turnover rates [34]). In addition, multiple anti-
genically distinctive populations of putative endogenous or
heart-derived stem cells (defined by an ability to differentiate
intomultiple cardiac lineages in vitro and in vivo), have nowbeen
identified in rodents and humans, including c-Kit (CD117, the
receptor for stem cell factor) [35] cells, Sca-1 (stem cell anti-
gen-1) [36] cells, side population cells (characterized by the abil-
ity to efflux metabolic markers such as Hoechst because of high
expression of membrane pumps) [37], cardiospheres (three-di-
mensional microtissues of heart stem cells and supporting cells)
[7], and hCDCs [8]. With a view to therapeutic application, we
have developed a technique to yield clinically relevant numbers
of cardiac stem cells and heart-derived stromal cells from small
amounts of starting tissue material (such as percutaneous endo-
myocardial biopsies) in a timely manner [8]. Cardiac biopsies are
minced and placed in primary culture, spontaneously shedding
outgrowth cells, which can be harvested by gentle enzymatic
digestion. When placed in suspension culture, these cells self-
organize into multicellular spherical clusters, termed CSps [7].
Figure 5. In vivo effect of trastuzumab. (A): Biweekly intraperitoneal injection of TZM for 3 weeks did not lead to left ventricular dysfunction
in SCID-beige mice. (B): Biweekly intraperitoneal administration of TZM abrogated the functional benefit of hCDCs injected into the border
zone of acutely infarcted murine left ventricular myocardium. Injection of hCDCs alone led to a 10% increase in ejection fraction compared
with animals that received hCDCs and TZM. Of note, there was no difference between the treatment group (hCDCs  TZM) and the two
negative control groups included in the study, that is, injection of human dermal fibroblasts and injection of PBS. (C):Differences in postinfarct
remodelingwere evident by a thinner infarct scar in animals receiving TZM,whereas thedifference in infarct area between the twogroupswas
not statistically significant (the numbers of animals are indicated on the bars). Abbreviations: EF, ejection fraction; hCDC, human cardio-
sphere-derived cells; NS, not significant; PBS, phosphate-buffered saline; TZM, trastuzumab.
Figure 6. In vivo effect on angiogenesis. (A): Representative images
of the infarct border zonemyocardiumof hCDCs PBS-treated (top)
and hCDCs  TZM-treated (bottom) animals, demonstrating a re-
duced number of capillaries in TZM-treated animals. Capillarieswere
stained with isolectin B4-fluorescein (green). Nuclei were stained
with 4,6-diamidino-2-phenylindole (blue) and with an antibody tar-
geting human nuclear antigen (red). (B): After capillaries were
stained with isolectin B4-fluorescein, green pixels were normalized
to the number of total nuclei in the imaged infarct border zone area.
Similar results were obtained when green pixels were divided by the
number of human nuclei, stained with an antibody targeting the
human nuclear antigen (Chemicon; data not shown). Images were
taken at 20 magnification. Scale bars  50 m. Abbreviations:
hCDC, human cardiosphere-derived cells; PBS, phosphate-buffered
saline; TZM, trastuzumab.
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CSps are replated and further expanded in monolayer culture to
yield CDCs. CDCs (in contrast to antigenically purified cells) are a
naturally heterogeneous cardiac-derived cell population of non-
hematological origin [38], rich in cardiac stem andmesenchymal
cells. When grown according to established methods, CDCs ex-
hibit clonogenicity, self-renewal capacity, and multipotentiality
[12], thus fulfilling key criteria for stem cells. In vivo, we have
demonstrated that CDCs can safely engraft and improve cardiac
function post-myocardial infarction (MI) (through both direct
and indirect mechanisms) in mice [6, 8, 9], rats [19, 23, 39], and
pigs [19, 20]. Importantly, CDCs can be safely delivered via the
intracoronary route within a defined dosage range [20]. These
cells differentiate primarily into cardiomyocytes and, to a lesser
extent, also into endothelial and smooth muscle cells [8, 12, 40].
Here, we demonstrated that hCDCs express ERBB2 receptors at
levels comparable to those of adult myocardium. Even though
TZMhad no effect on proliferation, apoptosis, or size of the c-kit-
positive hCDC subpopulation in vitro, the functional benefit of
hCDCs injected into the border zone of acutely infarcted immu-
nocompromised SCID-beige mice was abrogated by TZM in vivo.
Infarcted animals treated with TZM  hCDCs had a lower ejec-
tion fraction, a thinner infarct scar, and a reduced capillary den-
sity compared with animals that received hCDCs alone. Func-
tional in vitro assays demonstrated that hCDCs exposed to
clinically relevant concentrations of TZMwere functionally inhib-
ited, as demonstrated by diminished potential for early cardio-
genic differentiation and impaired ability to form microvascular
networks in angiogenesis assays. The neuregulin-1/ErbB-signal-
ing axis has been shown to enhance differentiation of cardiomy-
ocytes from embryonic stem cells [41–43] and to upregulate the
expression of the cardiac-restricted transcription factors Nkx2.5
andGATA-4 [42]. In linewith these findings, TZM led to a reduced
expression of markers of early cardiogenic differentiation in
hCDCs in the present study (Fig. 4).
Although ourwork identifies TZM-mediated inhibition of car-
diomyogenesis and angiogenesis as potential culprits, the rela-
tive roles of these parallel effects, in addition to known adverse
effects on cardiomyocytes, are as yet unclear. Given that the
median length of TZM therapy is limited to 12 months in the
adjuvant setting [2] but could exceed that in the metastatic set-
ting [26], prolonged inhibition of the physiologic turnover of car-
diomyocytes could impede the myocardium’s ability to recover
from myocardial injury. In addition to inhibitory effects on car-
diogenesis, trastuzumab’s antiangiogenic effects have been
well-documented, evident by downregulation of angiogenic fac-
tors such as vascular endothelial growth factor, angiopoetin-1,
plasminogen activator inhibitor-1, and thrombospondin 1 [44,
45]. In agreement with previous studies [8, 12], we found hCDCs
to express several endothelial surface markers, including CD31
and CD34, and to formmicrovascular tubes on a Matrigel angio-
genesis assay. However, there are important differences be-
tween hCDCs and endothelial cells (e.g., HUVECs) with respect to
angiogenesis. For instance, tube formation occurs much earlier
in hCDCs than in HUVECs (3–4 vs. 9–18 hours, respectively), pos-
sibly as a result of the mixed cell composition of hCDCs. The
recognition that angiogenesis in vivo involves not only endothe-
lial cells but also their surrounding cells has more recently led to
the use of organ culture methods to assess angiogenesis. Of
these, the rat aortic ring assay has become themostwidely used,
where the isolated rat aorta is cut into segments and placed in
culture, generally in a matrix-containing environment such as
Matrigel. Over the next 7–14 days, the explants are monitored
for the outgrowth of endothelial (and other) cells, as this is af-
fected by the addition of test substances [46]. In analogy to the
aortic ring assay, a microvascular network started to be seen as
early as 2–3 days after hCDCs were plated on Matrigel, and cells
continued to grow in medium containing 2.5% fetal bovine se-
rum for more than 4 weeks. Consistent with TZM’s antiangio-
genic properties, the size and complexity of the microvascular
outgrowth was dramatically inhibited in hCDCs cultured in
TZM-containing medium compared with control. Moreover,
TZM-treated animals had a reduced capillary density in the
infarct border zone compared with animals that received
hCDCs alone.
In line with the current results, previous studies have shown
that the assessment of cell number and viabilitymay not entirely
reflect the functional capacity of cells in vivo [17]. Differences in
cellular bioactivity due to distinct cell isolation protocols were
shown to be responsible for discrepant results in clinical trials
using bone marrow-derived progenitor cells for cardiac repair:
cells that retained their functional activity, determined by con-
ventional migration assays in Boyden chambers, showed a func-
tional benefit in vivo as manifested by a statistically significant
increase in ejection fraction, whereas clinical trials using cells
with impaired migratory response did not [17]. Likewise, the im-
portance of the cell isolation protocol was also highlighted in a
study by Assmus et al., demonstrating that contaminating red
blood cells affected the functionality of isolated bone marrow-
derived progenitor cells and suggesting a bioactivity response
relationship very much like a dose-response relationship in drug
trials [47]. The present study underscores the importance of
functional in vitro assays to test cellular bioactivity and potential
therapeutic efficacy of stem cells. Prospective studies are
needed to determine the relationship betweendifferences in the
results of angiogenesis and cardiogenic differentiation assays for
CDCs isolated from different patients and the cells’ functional
ability to promote cardiogenic repair.
CONCLUSION
Collectively, these results indicate that TZM inhibits the car-
diomyogenic and angiogenic capacities of hCDCs in vitro and ab-
rogates themorphological and functional benefits of hCDC trans-
plantation in vivo. Thus, functional impairment of human
resident cardiac stem cells may represent a novel mechanism of
TZM cardiotoxicity.
Study Limitations
The results of the present study indicate that TZM inhibits the
angiogenic potential of hCDCs in vitro. Although wewere able to
demonstrate that TZM slowed the growth and reduced the com-
plexity of the microvascular network, future studies need to ad-
dress whether the antiangiogenic effect of TZM is mediated by
inhibition of the migration or the angiogenic differentiation of
hCDCs, or both, in vitro and in vivo.
Althoughwe demonstrated that the cardiomyogenic and an-
giogenic capacities of hCDCs are inhibited in vitro by TZM, the
relative contributions of these mechanisms, in addition to direct
toxic effects on cardiomyocytes, to the overall adverse effect on
cardiac function deserve further exploration. In the present
study, we showed that TZMdid not affectmyocardial function of
healthymice. One potential limitation of the study is the absence
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of a trastuzumab-only group post-MI. It is theoretically possible
that TZM alone might have effects on the mouse myocardium,
such as inhibiting the cardiac healing potential post-MI. How-
ever, themarked species specificity of TZM for the human ERBB2
receptor makes such effects unlikely.
We demonstrated that ERBB2 is abundantly expressed in
hCDCs, which are a natural mixture of cardiac stem cells and
supporting cells with potent regenerative effects in vivo. Future
studies need to determine whether particular subpopulations of
hCDCs (e.g., c-kit-positive CDCs) express ERBB2 and whether the
ERBB2-expressing cells are different from other subpopulations
of hCDCs.
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